Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Preferred Stock Liabilities: 2011

Historic Preferred Stock Liabilities for Ligand Pharmaceuticals (LGND) over the last 1 years, with Dec 2011 value amounting to $8.3 million.

  • Ligand Pharmaceuticals' Preferred Stock Liabilities was N/A to $8.3 million in Q4 2011 from the same period last year, while for Dec 2011 it was $8.3 million, marking a year-over-year change of. This contributed to the annual value of $8.3 million for FY2011, which is N/A change from last year.
  • According to the latest figures from FY2011, Ligand Pharmaceuticals' Preferred Stock Liabilities is $8.3 million.
  • Over the past 5 years, Ligand Pharmaceuticals' Preferred Stock Liabilities peaked at $8.3 million during FY2011, and registered a low of $8.3 million during FY2011.
  • In the last 1 years, Ligand Pharmaceuticals' Preferred Stock Liabilities had a median value of $8.3 million in 2011 and averaged $8.3 million.